title: A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
abstract: The functional role of cholecystokinin in the central nervous system is unknown. The tetra peptide CCK-4 was previously observed to induce panic attacks in a majority of normal volunteers and patients with panic disorder. Furthermore, it had been demonstrated that pretreatment with 10-50 mg of L-365,260, a selective CCKB antagonist, blocked CCK-4 induced panic in patients with panic disorder. Therefore, the present multicenter, placebo-controlled, double-blind trial was designed to investigate the efficacy of L-365,260, a CCKB antagonist, in patients with panic disorder with or without agoraphobia. Following a 1-week, single-blind placebo period, 88 patients were randomized to double-blind treatment in which they received either L-365,260, 30 mg qid, or placebo for 6 weeks. At the dose tested, there were no clinically significant differences between L-365,260 and placebo in global improvement ratings, Hamilton anxiety rating scale scores, panic attack frequency, panic attack intensity, or disability measures. The possible reasons for lack of effect with L-365,260 are discussed.
authors.affiliation: Merck Research Laboratories, West Point, PA 19486, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Kramer
authors.forename: N R
authors.initials: NR
authors.lastname: Cutler
authors.forename: J C
authors.initials: JC
authors.lastname: Ballenger
authors.forename: W M
authors.initials: WM
authors.lastname: Patterson
authors.forename: J
authors.initials: J
authors.lastname: Mendels
authors.forename: A
authors.initials: A
authors.lastname: Chenault
authors.forename: R
authors.initials: R
authors.lastname: Shrivastava
authors.forename: D
authors.initials: D
authors.lastname: Matzura-Wolfe
authors.forename: C
authors.initials: C
authors.lastname: Lines
authors.forename: S
authors.initials: S
authors.lastname: Reines
mesh_terms: D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy / Q000523:psychology; D001143:Arousal / Q000187:drug effects; D001570:Benzodiazepinones / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy* / Q000523:psychology; D010555:Personality Inventory; D010671:Phenylurea Compounds; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D013758:Tetragastrin; D016896:Treatment Outcome
chemical_list: D001570:Benzodiazepinones; D010671:Phenylurea Compounds; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D013758:Tetragastrin; C058121:L 365260